» Articles » PMID: 38282346

From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function

Overview
Journal Med Sci Monit
Date 2024 Jan 29
PMID 38282346
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic dysfunction-associated fatty liver disease or metabolic dysfunction-associated steatotic liver disease (MAFLD/MASLD), is a common chronic liver condition affecting a substantial global population. Beyond its primary impact on liver function, MAFLD/MASLD is associated with a myriad of extrahepatic manifestations, including cognitive impairment. The scope of cognitive impairment within the realm of MAFLD/MASLD is a matter of escalating concern. Positioned as an intermediate stage between the normal aging process and the onset of dementia, cognitive impairment manifests as a substantial challenge associated with this liver condition. Insights from studies underscore the presence of compromised executive function and a global decline in cognitive capabilities among individuals identified as being at risk of progressing to liver fibrosis. Importantly, this cognitive impairment transcends mere association with metabolic factors, delving deep into the intricate pathophysiology characterizing MAFLD/MASLD. The multifaceted nature of cognitive impairment in the context of MAFLD/MASLD is underlined by a spectrum of factors, prominently featuring insulin resistance, lipotoxicity, and systemic inflammation as pivotal contributors. These factors interplay within the intricate landscape of MAFLD/MASLD, fostering a nuanced understanding of the links between hepatic health and cognitive function. By synthesizing the available evidence, exploring potential mechanisms, and assessing clinical implications, the overarching aim of this review is to contribute to a more complete understanding of the impact of MAFLD/MASLD on cognitive function.

Citing Articles

Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review.

Ramesh P, Krishnan P, Prabu S, Srinivasan V, Niranjan V Obes Pillars. 2024; 12:100142.

PMID: 39498281 PMC: 11532278. DOI: 10.1016/j.obpill.2024.100142.


Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy.

Jimenez V, Sacristan V, Jambrina C, Jaen M, Casana E, Munoz S Mol Ther. 2024; 32(12):4285-4302.

PMID: 39489916 PMC: 11638876. DOI: 10.1016/j.ymthe.2024.10.023.


Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols.

Tauil R, Golono P, de Lima E, de Alvares Goulart R, Landgraf Guiguer E, Bechara M Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458995 PMC: 11510109. DOI: 10.3390/ph17101354.


Interaction between trouble sleeping and diabetes on metabolic dysfunction-associated fatty liver disease and liver fibrosis in adults results from the National Health and Nutrition Examination Survey 2017-2018.

Zhang C, Cao L, Xu B, Zhang W Eur J Gastroenterol Hepatol. 2024; 36(12):1437-1446.

PMID: 39373628 PMC: 11527372. DOI: 10.1097/MEG.0000000000002860.


Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study.

Pujol A, Sanchis P, Tamayo M, Godoy S, Calvo P, Olmos A Biomedicines. 2024; 12(9).

PMID: 39335505 PMC: 11428552. DOI: 10.3390/biomedicines12091993.


References
1.
Balp M, Krieger N, Przybysz R, Way N, Cai J, Zappe D . The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. JHEP Rep. 2020; 1(3):154-161. PMC: 7001541. DOI: 10.1016/j.jhepr.2019.05.009. View

2.
Wang J, Zhu N, Su X, Gao Y, Yang R . Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis. Cells. 2023; 12(5). PMC: 10000530. DOI: 10.3390/cells12050793. View

3.
Ding J, Jin Z, Yang X, Lou J, Shan W, Hu Y . Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World J Gastroenterol. 2020; 26(40):6141-6162. PMC: 7596643. DOI: 10.3748/wjg.v26.i40.6141. View

4.
Misiak B, Leszek J, Kiejna A . Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity. Brain Res Bull. 2012; 89(3-4):144-9. DOI: 10.1016/j.brainresbull.2012.08.003. View

5.
Kjaergaard K, Mikkelsen A, Wernberg C, Gronkjaer L, Eriksen P, Damholdt M . Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. J Clin Med. 2021; 10(4). PMC: 7916374. DOI: 10.3390/jcm10040673. View